SEC Form 10-Q filed by Rapid Micro Biosystems Inc.
$RPID
Biotechnology: Laboratory Analytical Instruments
Industrials
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/28/2025 | $8.00 | Buy | Lake Street |
| 2/12/2025 | $8.00 | Overweight | KeyBanc Capital Markets |
| 8/16/2022 | Overweight → Neutral | JP Morgan | |
| 3/7/2022 | $11.00 → $10.00 | Equal-Weight | Morgan Stanley |
| 2/15/2022 | $24.00 → $11.00 | Equal-Weight | Morgan Stanley |
| 11/15/2021 | $26.00 → $24.00 | Equal-Weight | Morgan Stanley |
| 8/9/2021 | Outperform | Cowen | |
| 8/9/2021 | $26.00 | Equal-Weight | Morgan Stanley |
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
Lake Street initiated coverage of Rapid Micro Biosystems with a rating of Buy and set a new price target of $8.00
KeyBanc Capital Markets initiated coverage of Rapid Micro Biosystems with a rating of Overweight and set a new price target of $8.00
JP Morgan downgraded Rapid Micro Biosystems from Overweight to Neutral
10-Q - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
10-Q - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)
Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, increased 32% compared to the third quarter of 2024 driven by record consumable revenue. Reports third quarter gross margin of 9%, representing a 70-basis point improvement compared to the third quarter of 2024.Announces record multi-system order from an existing Top 20 global biopharma customer to automate global manufacturing network. Raises full year 2025 total revenue guidance to at least $33.0 million, which assumes at least 27 Growth Direct system placements. LEXINGTON, Mas
LEXINGTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2025 Healthcare Conference in New York, NY. Company management is scheduled to participate in a 30-minute question-and-answer session with the host analyst on Tuesday, November 11, 2025, at 11:20 a.m. ET. A live webcast will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ an
LEXINGTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2025 financial results prior to the market open on Friday, November 7, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, November 7, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for rep
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
4 - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Issuer)
Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, increased 32% compared to the third quarter of 2024 driven by record consumable revenue. Reports third quarter gross margin of 9%, representing a 70-basis point improvement compared to the third quarter of 2024.Announces record multi-system order from an existing Top 20 global biopharma customer to automate global manufacturing network. Raises full year 2025 total revenue guidance to at least $33.0 million, which assumes at least 27 Growth Direct system placements. LEXINGTON, Mas
LEXINGTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2025 financial results prior to the market open on Friday, November 7, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, November 7, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for rep
Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024. Reports second quarter gross margin of 4%, representing a seven-percentage point improvement compared to the second quarter of 2024. Enters into five-year, $45 million term loan facility with $20 million funded at close. Reaffirms full-year 2025 total revenue guidance of at least $32.0 million. LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology c
LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company" or "Rapid Micro"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to welcome Dr. Dafni Bika to the Company's Board of Directors (the "Board"). "We are extremely pleased to welcome Dr. Bika to our Board of Directors," said Robert Spignesi, President and Chief Executive Officer. "Dafni has more than 25 years of leadership experience in pharmaceutical development and manufacturing science and technology. She brings a wealth of knowledge an
LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Kirk Malloy, Ph.D. as Chair of the Company's Board of Directors (the "Board"). Dr. Malloy will also Chair the Board's Compensation Committee. Jeffrey Schwartz, who previously served as Board Chair, remains a member of the Board and continues to serve as Chair of the Nominating and Corporate Governance Committee. "We are very excited to welcome Kirk to our Boar
LOWELL, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the appointment of Michael Wysocki to the position of Senior Vice President, Sales and Marketing. Wysocki joins the Company with nearly two decades of experience at General Electric and GE Healthcare. During his GE career, he held roles of increasing responsibility in their imaging, molecular imaging and computed tomography (CT) businesses before becoming the General Manager, U.S
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)
SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)